Abstracts tagged "population studies"

Abstract Number: 0132 • ACR Convergence 2021
Hospitalization Rates Among Patients with Systemic Lupus Erythematosus: A Population Based Study
Jesse Dabit¹, Mehmet Hocaoglu², Maria Valenzuela-Almada³, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Rachel Giblon¹, Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune multiorgan disease associated with significant morbidity and mortality. Although the survival rate for SLE patients has…
Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Sahil Koppikar¹, Bindee Kuriya², Jacob Udell³, Bing Yu⁴, Anna Chu⁴, Laura Ferreira-Legere⁵, Douglas Lee³, Jessica Widdifield⁶ and Lihi Eder³, ¹Women's College Hospital, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴ICES, Toronto, ON, Canada, ⁵ICES, Toronto, Canada, ⁶Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…
Abstract Number: 0332 • ACR Convergence 2021
Prevalence of Systemic Lupus Erythematosus in the United States: Updated Population Representative Estimates from the Medical Expenditure Panel Survey (MEPS) 2016-2018
Michael Pollack¹, Sandra Sze-jung Wu¹, Eilleen Farrelly², Shannon Grabich³ and Robert Ortmann⁴, ¹AstraZeneca, Wilmington, DE, ²Xcenda, Carrollton, TX, ³Xcenda, Durham, NC, ⁴AstraZeneca, Greenwood, IN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-organ, autoimmune disease whose prevalence in the US has not been recently updated in real-world studies. Prevalence…
Abstract Number: 0377 • ACR Convergence 2021
The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands
Stan Kieskamp, Suzanne Arends, Elisabeth Brouwer, Hendrika Bootsma, Ilja Nolte and Anneke Spoorenberg, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Chronic low back pain (CLBP; back pain >3 months) with onset at age < 45 and inflammatory back pain (IBP) are regarded as early…
Abstract Number: 0060 • ACR Convergence 2020
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Sandy Lee¹, Patil Injean¹, Paulina Tran², Deepa Panikkath¹ and Christina Downey¹, ¹Loma Linda University Medical Center, Redlands, CA, ²UC Riverside School of Medicine, Riverside, CA
Background/Purpose: ANCA-associated vasculitis (AAV) is often studied in the Caucasian population with few studies looking at the disease in other races. Disease presentation and treatment…
Abstract Number: 0638 • ACR Convergence 2020
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
Cristobal Pavez Perales¹, Samuel Leal Rodriguez², Marta De la Rubia Navarro¹, Roxana Gonzalez Mazario¹, Elena Grau Garcia³, Cristina Alcañiz Escandell³, Inmaculada Chalmeta Verdejo¹, Jorge Juan Fragio Gil¹, Luis Gonzalez Puig⁴, Jose Ivorra Cortes¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz Sanjuan⁵, Elvira Vicens Bernabeu² and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department, HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain, ⁵La Fe University Hospital, Valencia
Background/Purpose: In mid-March 2020, state of alarm was declared in Spain due to the novel coronavirus disease 2019 (COVID-19) pandemic. Patients with rheumatic diseases (RD)…
Abstract Number: 0095 • ACR Convergence 2020
Systematic Evaluation of Nine Monogenic Autoinflammatory Diseases Reveals Common and Disease-Specific Correlations with Allergy-Associated Features
Moses Kitakule¹, Brian Dizon², Cristhian Gutierrez-Huerta¹, Sarah Blackstone², Aarohan Burma¹, Aran Son¹, Natalie Deuitch¹, Sofia Rosenzweig¹, Hirsh Komarow¹, Deborah Stone³, Anne Jones⁴, Michele Nehrbecky¹, Patrycja Hoffmann⁵, Tina Romeo⁶, Adriana de Jesus⁷, Sara Alehashemi⁸, Megha Garg⁹, Sofia Torreggiani¹⁰, Gina Montealegre Sanchez¹¹, Katelin R. Honer¹⁰, Karyl Barron¹, Ivona Aksentijevich⁴, Amanda Ombrello¹², Raphaela Goldbach-Mansky¹³, Daniel Kastner¹⁴, Joshua Milner¹⁵, Pamela Frischmeyer-Guerrerio¹ and Daniella Schwartz¹⁶, ¹National Institutes of Health, Bethesda, ²National Institutes of Health, BETHESDA, MD, ³NIH, Bethesda, ⁴National Human Genome Research Institute, Bethesda, MD, ⁵NIH, Vienna, VA, ⁶NIH, Bethesda, MD, ⁷Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁸Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ⁹NIH/NIAID, Rochester, NY, ¹⁰Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ¹¹NIAID/NIH, Rockville, MD, ¹²National Human Genome Research Institute/National Institutes of Health, Bethesda, MD, ¹³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, ¹⁴National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ¹⁵Division of Allergy, Immunology and Rheumatology Columbia University Medical Center, New York, NY, ¹⁶National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Monogenic autoinflammatory diseases (AID) are caused by mutations in innate immune signaling genes. The effect of these mutations on the risk of allergy is…
Abstract Number: 0642 • ACR Convergence 2020
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
Marta González Fernández¹, Orlando Pompei fernández², Joaquín María Belzunegui Otano³, Paula García Escudero¹, Claudia Stoye², Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0130 • ACR Convergence 2020
The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review
Timothy Varghese¹, Ali Ahmadi Pirshahid², Dongkeun Kim² and Yueyang Li², ¹Schulich School of Medicine & Dentistry, Richmond Hill, ON, Canada, ²Schulich School of Medicine & Dentistry, London, ON, Canada
Background/Purpose: There is controversy regarding the relationship between osteoarthritis (OA) and osteoporosis (OP). While OA may be associated with increased bone mineral density (BMD) due…
Abstract Number: 0657 • ACR Convergence 2020
Gout and Heart Failure in the US
Gurkipal Singh¹, Maanek Sehgal² and Alka Mithal³, ¹Stanford University, Stanford, CA, ²UCLA, Los Angeles, CA, ³ICORE, Woodside, CA
Background/Purpose: Heart failure (HF) is the eighth leading cause of death in the US, with a 38% increase in the number of deaths due to…
Abstract Number: 0308 • ACR Convergence 2020
Delay in Transition from Psoriasis to Psoriatic Arthritis: A Population Based Study
Paras Karmacharya¹, Kerry Wright², Sara J. Achenbach³, Delamo Bekele², Cynthia Crowson⁴, Alexis Ogdie⁵, Ali Duarte-Garcia², Floranne C. Ernste³, Megha M. Tollefson¹ and John Davis², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently or after the development of psoriasis. In order to better understand the…
Abstract Number: 0665 • ACR Convergence 2020
Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study
Brian LaMoreaux¹, John Botson², Megan Francis-Sedlak¹, Karl Svensson¹ and Robert Holt¹, ¹Horizon Therapeutics plc, Lake Forest, IL, ²Orthopedic Physicians Alaska, Anchorage, AK
Background/Purpose: Pegloticase, a recombinant, PEGylated uricase enzyme, is used to treat uncontrolled gout in patients who do not improve on or are intolerant of oral…
Abstract Number: 0309 • ACR Convergence 2020
Diagnostic Delay in Psoriatic Arthritis: A Population Based Study
Paras Karmacharya¹, Kerry Wright², Sara J. Achenbach³, Delamo Bekele², Cynthia Crowson⁴, Alexis Ogdie⁵, Ali Duarte-Garcia², Floranne C. Ernste³, Megha M. Tollefson¹ and John Davis², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is important for improving long-term outcomes. Trends in diagnostic delay of PsA in the US and factors associated…
Abstract Number: 0673 • ACR Convergence 2020
Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
Brian LaMoreaux¹, Megan Francis-Sedlak¹, Scott Neville² and Robert Holt¹, ¹Horizon Therapeutics plc, Lake Forest, IL, ²Foot and Ankle Center, Mooresville, IN
Background/Purpose: Gout can cause uric acid deposition in joints, soft tissues, and organs (1) and is associated with heart disease, kidney disease, hypertension, hyperlipidemia, diabetes,…
Abstract Number: 0342 • ACR Convergence 2020
Multimorbidity Clusters in Psoriatic Arthritis: A Population-Based Study
Paras Karmacharya¹, Dilli Poudel², Cynthia Crowson³, John Davis⁴, Kerry Wright⁴ and Alexis Ogdie², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Psoriatic arthritis (PsA) patients have a higher prevalence of cardiometabolic and other morbidities compared to the general population. Studies suggest that a single clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].